Effects of Laparoscopic Adjustable Gastric Banding on Weight Loss, Metabolism, and Obesity-Related Comorbidities: 5-year Results in China

详细信息    查看全文

• 作者：Jie Fan (1)
  Jian Hui Xu (2)
  Jia Wang (3)
  Gui Zhen Wang (4)
  You Qin Zhang (7)
  Xing Zhen Liu (5) (6)
  
• 关键词：Laparoscopic adjustable gastric banding ; Bariatric surgery ; Obesity ; Long term ; Weight loss ; Metabolism
• 刊名：Obesity Surgery
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：24
• 期：6
• 页码：891-896
• 全文大小：
• 参考文献：1. Salem L, Devlin A, et al. A cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding and non-surgical weight loss interventions. Surg Obes Relat Dis. 2008;4:26-2. CrossRef
  2. Al Khalifa K, Violato C, et al. Reduction in weight and BMI and changes in Co-morbidities following laparoscopic adjustable gastricbanding procedure for morbidly obese patients in Bahrain: a five year longitudinal study. Springerplus. 2013;2(1):19. CrossRef
  3. Ferguson RD, Gallagher EJ, et al. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm. 2013;93:51-8. CrossRef
  4. Wolfe BM, Purnell JQ, et al. Treating diabetes with surgery. JAMA. 2013;21:2274-. CrossRef
  5. O’Brien PE, MacDonald L, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87-4. CrossRef
  6. Dixon JB, Murphy DK, et al. Impact of laparoscopic adjustable gastric banding on type 2 diabetes. Obes Rev. 2012;13(1):57-7. CrossRef
  7. Caiazzo R, Arnalsteen L, et al. Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose. Br J Surg. 2010;97(6):884-1. CrossRef
  8. Deitel M, Gawdat K, et al. Reporting weight loss 2007. Obes Surg. 2007;17:565-. CrossRef
  9. Wallace TM, Levy JC, et al. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-5. CrossRef
  10. Buse JB et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133-. CrossRef
  11. US Food and Drug Administration. FDA expands use of banding system for weight loss [press release on the Internet]. Washington, DC: US Department of Health and Human Services 2011 Feb 16. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm (accessed July 26, 2013).
  12. Wang CC, Zhai HN. Standardize and pragmatism-the key to promote the healthy development of obesity and metabolic surgery in China. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15(11):1102-. Article in Chinese.
  13. Angrisani L, Cutolo PP. Long-term outcomes of laparoscopic adjustable silicone gastric banding (LAGB) in moderately obese patients with and without co-morbidities. Obes Surg. 2013;23(7):897-02. CrossRef
  14. Busetto L, Angrisani L, et al. Safety and efficacy of laparoscopic adjustable gastric banding in the elderly. Obesity (Silver Spring). 2008;16(2):334-. CrossRef
  15. Chevallier JM, Paita M, et al. Predictive factors of outcome after gastric banding: a nationwide survey on the role of center activity and patients' behavior. Ann Surg. 2007;246(6):1034-. CrossRef
  16. Abbatini F et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24(5):1005-0. CrossRef
  17. Wang S, Li P, et al. Comparison between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding for morbid obesity: a meta-analysis. Obes Surg. 2013;23(7):980-. CrossRef
  18. Samat A, Malin SK, et al. Ghrelin suppression is associated with weight loss and insulin action following gastric bypass surgery at 12 months in obese adults with type 2 diabetes. Diabetes Obes Metab. 2013 Epub May 16.
  19. Peterli R, Steinert RE, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740-. CrossRef
  20. Brancatisano A, Wahlroos S, et al. Improvement in comorbid illness after placement of the Swedish Adjustable Gastric Band. Surg Obes Relat Dis. 2008;4(3):39-6. CrossRef
  
• 作者单位：Jie Fan (1)
  Jian Hui Xu (2)
  Jia Wang (3)
  Gui Zhen Wang (4)
  You Qin Zhang (7)
  Xing Zhen Liu (5) (6)
  
  1. Department One, Hangzhou Sanatorium of Nanjing Military Region, Hangzhou, Zhejiang, 310007, China
  2. 73171 Hospital of PLA, Nanjing Military Region, Shanghai, 200433, China
  3. Department of Endocrinology, Jinan General Hospital of Guangzhou Military Command Region, Jinan, Shandong, 250013, China
  4. Department of ICU, Urumuqi General Hospital of Lanzhou Military Command Region, Urumuqi, 830000, China
  7. Department of Nursing, Hangzhou Sanatorium of Nanjing Military Region, Hangzhou, Zhejiang, 310007, China
  5. Department of Endocrinology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China
  6. Hangzhou Sanatorium of Nanjing Military Region, Hangzhou, Zhejiang, 310007, China
  
• ISSN：1708-0428

文摘

Background Despite some reports about the long-term metabolic outcomes after laparoscopic adjustable gastric banding (LAGB) in the Western populations, there are few reports on the Asian population whose body size and fat distribution are different. Therefore, this study was conducted to evaluate the medium-term effects of LAGB on weight loss and metabolic outcomes of obese patients with different body mass index (BMI) in China. Methods A retrospective study was performed to review the 5-year follow-up data of 56 patients (18 males, 38 females) who received LAGB from November 2003 to May 2013 at the Shanghai Changhai Hospital. The patients were evaluated at years 1, 3, and 5 after operation in the outpatient clinic, and the weight loss, metabolic parameters, and remission of comorbidities were measured. Results The 56 patients preoperatively had BMI of 37.4?±-.0?kg/m2, with BMI-lt;-5?kg/m2 in 19 patients (BMI <35?kg/m2 group), and BMI?≥-5?kg/m2 in 37 patients (BMI?≥-5?kg/m2 group). The percentages of excess weight loss (%EWL) of the BMI-lt;-5?kg/m2 group at years 1, 3, and 5 were 65.2, 65.6, and 65.7?%, respectively, indicating the majority of metabolic parameters were significantly improved (P-lt;-.05). However, in the BMI?≥-5?kg/m2 group, the %EWL were 37.9, 34.8, and 26.5?%, respectively, except at year 1 when the metabolic parameters improved significantly (P-lt;-.05), those at year 3 and year 5 did not significantly improve compared with the preoperative levels. Similar results were observed in the improvement of comorbidities. Conclusions Relatively low medium-term weight loss, metabolic improvement, and resolution or remission of obesity-related comorbidities and high reoperation rate were observed in our population of patients with BMI?≥-5?kg/m2 who underwent LAGB.